SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Galapagos Islands -- Ignore unavailable to you. Want to Upgrade?


To: PuddleGlum who wrote (41080)6/1/2003 10:21:59 PM
From: Lizzie Tudor  Read Replies (1) | Respond to of 57110
 
thanks great info!

That sector seems like it goes from spec bubble to spec bubble, year after year.



To: PuddleGlum who wrote (41080)6/1/2003 11:15:41 PM
From: Techplayer  Respond to of 57110
 
PG, There were comments on briefing on either Thursday or Friday about the Cancer conference this weekend. MLNM was one of several mentioned that would likely benefit positively. what that means for the stock price is anyone's guess. 3-4 months ago, the feeling would likely have been that it has come too far too fast. We are obviously in a different market now.

MLNM was one of my picks for the first q contest. Since the end of March, it has nearly doubled. Nice move for those that bought and held.

It will be interesting to see what PIXR does this week. Massive short % and a record breaking movie weekend...



To: PuddleGlum who wrote (41080)6/2/2003 12:13:36 AM
From: Libbyt  Read Replies (1) | Respond to of 57110
 
I think that ASCO results are already priced into the biotech sector.... how much higher do we go before the selling starts?

IMO the biotech sector will go higher...since the ASCO results will probably "fuel" the move to even higher prices.

When DNA is mentioned in a positive article, REGN seems to benefit from their news...and it also seems to be moving higher along with other companies in this sector.